论文部分内容阅读
目的探讨肿瘤干细胞标志物CD133在乳腺癌组织中的表达及其临床意义。方法采用免疫组织化学方法检测109例乳腺癌组织和60例乳腺良性肿瘤组织中CD133的表达,分析其与乳腺癌亚型及临床病理参数间的关系。结果109例乳腺癌组织中,CD133表达的阳性率为46.8%(51/109),60例乳腺良性肿瘤的阳性率为0.33%(2/60),两者差异具有高度统计学意义(P<0.01);109例乳腺癌组织中,CD133蛋白的表达随病理级别的增加而升高(P<0.05),随临床分期升高及肿瘤直径增大呈下降趋势(P>0.05);乳腺癌4种亚群中,Basal-like亚群中CD133蛋白的阳性率最高,为69.2%,显著高于其他亚群,差异有统计学意义(P<0.05)。结论早期低分化或未分化癌更富于干细胞,可能与肿瘤细胞恶性演进有关;CD133蛋白的表达具有区分不同乳腺癌亚型作用以及在乳腺癌的预后预测具有重要作用。
Objective To investigate the expression of tumor stem cell marker CD133 in breast cancer and its clinical significance. Methods Immunohistochemical method was used to detect the expression of CD133 in 109 cases of breast cancer and 60 cases of benign breast neoplasm. The relationship between the expression of CD133 and the subtypes of breast cancer and clinicopathological parameters was analyzed. Results The positive rate of CD133 expression in 109 cases of breast cancer was 46.8% (51/109), and the positive rate of 60 cases of benign breast tumors was 0.33% (2/60) (P < 0.01). The expression of CD133 protein in 109 breast cancer tissues increased with the increase of pathological grade (P <0.05), and decreased with the increase of clinical stage and tumor diameter (P> 0.05). The expression of CD133 protein in breast cancer 4 The positive rate of CD133 protein in Basal-like subpopulation was the highest (69.2%), which was significantly higher than that in other subpopulations (P <0.05). Conclusions Early poorly differentiated or undifferentiated carcinoma is more abundant in stem cells and may be related to malignant progression of tumor cells. The expression of CD133 protein may play an important role in differentiating different subtypes of breast cancer and predicting the prognosis of breast cancer.